Dayton Misfeldt Net Worth

The estimated Net Worth of Dayton Misfeldt is at least $11.9 Million dollars as of 27 October 2017. Mr. Misfeldt owns over 400,000 units of Sunesis Pharmaceuticals Inc stock worth over $162,026 and over the last 16 years he sold SNSS stock worth over $11,736,812. In addition, he makes $0 as Chief Executive Officer, Principal Financial Officer, Secretary, and Director at Sunesis Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Misfeldt SNSS stock SEC Form 4 insiders trading

Dayton has made over 8 trades of the Sunesis Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 400,000 units of SNSS stock worth $800,000 on 27 October 2017.

The largest trade he's ever made was buying 23,824,450 units of Sunesis Pharmaceuticals Inc stock on 30 June 2010 worth over $6,670,846. On average, Dayton trades about 1,201,610 units every 107 days since 2009. As of 27 October 2017 he still owns at least 30,456 units of Sunesis Pharmaceuticals Inc stock.

You can see the complete history of Mr. Misfeldt stock trades at the bottom of the page.

Dayton Misfeldt biography

Dayton C. Misfeldt serves as Chief Executive Officer, Principal Financial Officer, Secretary, Director of the Company. He has served as a member of the Board since 2009. Mr. Misfeldt is a Managing Director of Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego.

How old is Dayton Misfeldt?

Dayton Misfeldt is 44, he's been the Chief Executive Officer, Principal Financial Officer, Secretary, and Director of Sunesis Pharmaceuticals Inc since 2020. There are 8 older and no younger executives at Sunesis Pharmaceuticals Inc. The oldest executive at Sunesis Pharmaceuticals Inc is H. Ward Wolff, 71, who is the Director.

What's Dayton Misfeldt's mailing address?

Dayton's mailing address filed with the SEC is SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, STE. 400, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Sunesis Pharmaceuticals Inc

Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.

What does Sunesis Pharmaceuticals Inc do?

Complete history of Mr. Misfeldt stock trades at Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc executives and stock owners

Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Adam Craig,
  Executive Vice President - Development, Chief Medical Officer
• Stephen Ketchum,
  Director
• David Stump,
  Independent Director
• Homer Pearce,
  Independent Director
• Nicole Onetto,
  Independent Director
• Matthew Fust,
  Independent Director
• Steve Carchedi,
  Independent Director
• H. Ward Wolff,
  Director
• Tina Gullotta,
  Principal Accounting Officer, Vice President - Finance
• Dayton Misfeldt,
  Chief Executive Officer, Principal Financial Officer, Secretary, Director
• James Young,
  Non-Executive Independent Chairman of the Board
• Eric Bjerkholt,
  EVP, CFO & Corp. Secretary
• Geoffrey M. Parker,
  Director
• Steven B Ketchum,
  Director
• Daniel N Jr Swisher,
  President and CEO
• Oncology Impact Management ...,
  
• William P. Quinn,
  See Remarks
• Judith A. Fox,
  See Remarks
• Patrick J Kerins,
  10% owner
• Ryan D Drant,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Equity Opportunities Fund, ...,
  
• City Capital Llc Bay City C...,
  
• Scott D Sandell,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Helen Susan Kim,
  Director
• Joseph I De Pinto,
  EVP, CCO
• Biopharma Partners Iii Lpal...,
  
• Equity Opportunities Fund, ...,
  
• Robert Scott Mc Dowell,
  Vice President, Research
• Edward Hurwitz,
  Director
• Dominique Semon,
  10% owner
• Biopharma Partners Iii Lpal...,
  
• Iii Eugene A Trainor,
  10% owner
• Charles M Linehan,
  10% owner
• Equity Opportunities Fund, ...,
  
• Pincus Equity Partners Lpwa...,
  
• Valerie L Pierce,
  Sr. VP, GC & Corp. Secretary
• Anthony B Evnin,
  Director
• Steven D Goldby,
  Director
• James A Wells,
  Director
• Stephen P A Fodor,
  Director
• Idec Incbiogen Idec Ma Inc ...,
  
• Pincus Equity Partners Lpwa...,
  
• Daniel C Md Adelman,
  Senior VP,Drug Discovery & Dev
• Ixmayfield Ix Management Ll...,
  
• Jonathan S Leff,
  Director
• Daryl B Winter,
  SVP,Gen Counsel/Corp Secretary
• Capital Iv, Lp Aisling Capi...,